{"id":555553,"date":"2026-06-02T21:58:31","date_gmt":"2026-06-02T19:58:31","guid":{"rendered":"https:\/\/medizinonline.com\/?p=555553"},"modified":"2026-06-02T21:58:41","modified_gmt":"2026-06-02T19:58:41","slug":"gli-inibitori-sglt2-presentano-vantaggi-rispetto-agli-inibitori-della-dpp4","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/it\/gli-inibitori-sglt2-presentano-vantaggi-rispetto-agli-inibitori-della-dpp4\/","title":{"rendered":"Gli inibitori SGLT2 presentano vantaggi rispetto agli inibitori della DPP4"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Gli inibitori SGLT2 sono associati a un rischio significativamente inferiore di demenza, compresa la malattia di Alzheimer e la demenza vascolare, rispetto agli inibitori DPP4. Il beneficio osservato era coerente in diversi sottogruppi ed era particolarmente evidente per dapagliflozin ed empagliflozin, mentre non c&#8217;era un effetto chiaro per altri agenti. <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/it\/il-mio-conto\/pacchetti\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/it\/effettuare-il-login\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fit%2Fgli-inibitori-sglt2-presentano-vantaggi-rispetto-agli-inibitori-della-dpp4%2F\">Accedi<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Gli inibitori SGLT2 sono associati a un rischio significativamente inferiore di demenza, compresa la malattia di Alzheimer e la demenza vascolare, rispetto agli inibitori DPP4. Il beneficio osservato era coerente&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/it\/il-mio-conto\/pacchetti\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/it\/effettuare-il-login\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fit%2Fgli-inibitori-sglt2-presentano-vantaggi-rispetto-agli-inibitori-della-dpp4%2F\">Accedi<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":555554,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Rischio di demenza con il diabete di tipo 2  ","footnotes":""},"category":[11392,11452,11519,11355,11371,11479,11550,11515],"tags":[23402,12131,30936,15063,63635,33444,41538],"powerkit_post_featured":[],"class_list":["post-555553","post","type-post","status-publish","format-standard","has-post-thumbnail","category-endocrinologia-e-diabetologia","category-farmacologia-e-tossicologia","category-formazione-continua","category-geriatria-it","category-neurologia-it","category-psichiatria-e-psicoterapia","category-rx-it","category-studi","tag-dapagliflozin-it","tag-demenza","tag-demenza-di-alzheimer","tag-demenza-vascolare","tag-inibitore-della-dpp4","tag-inibitori-sglt2-it","tag-rischio-di-demenza","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-06-11 01:23:00","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"it_IT","wpml_translations":{"pt_PT":{"locale":"pt_PT","id":555550,"slug":"inibidores-sglt2-com-vantagens-em-relacao-aos-inibidores-dpp4","post_title":"Inibidores SGLT2 com vantagens em rela\u00e7\u00e3o aos inibidores DPP4","href":"https:\/\/medizinonline.com\/pt-pt\/inibidores-sglt2-com-vantagens-em-relacao-aos-inibidores-dpp4\/"},"es_ES":{"locale":"es_ES","id":555563,"slug":"inhibidores-sglt2-con-ventajas-frente-a-los-inhibidores-dpp4","post_title":"Inhibidores SGLT2 con ventajas frente a los inhibidores DPP4","href":"https:\/\/medizinonline.com\/es\/inhibidores-sglt2-con-ventajas-frente-a-los-inhibidores-dpp4\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts\/555553","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/comments?post=555553"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts\/555553\/revisions"}],"predecessor-version":[{"id":555555,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/posts\/555553\/revisions\/555555"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/media\/555554"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/media?parent=555553"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/category?post=555553"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/tags?post=555553"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/it\/wp-json\/wp\/v2\/powerkit_post_featured?post=555553"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}